Is there a GLP-1 patch?
Direct answer
What you need to know
Evidence strength: StrongNo. There is no FDA-approved transdermal GLP-1 patch, and this is not a gap waiting to be filled — it is a chemistry problem. Semaglutide has a molecular weight of about 4,113.58 Daltons. The long-established upper limit for a molecule passively crossing intact skin is around 500 Daltons. Semaglutide is roughly 8 times too large. Products sold as “GLP-1 patches” contain no GLP-1 receptor agonist.
Key takeaways
- No GLP-1 receptor agonist is approved in any transdermal form, in any country we could verify.
- The barrier is molecular size, not regulatory delay.
- Patches sold under this name are typically herbal or “acupressure” products, not medicines.
- If you can buy it without a prescription, it is not a GLP-1 drug.
Important limitation: Research into enhanced transdermal peptide delivery — microneedles, iontophoresis, chemical permeation enhancers — is a real scientific field. Nothing in it has produced an approved GLP-1 patch, and none of it applies to a sticker you can buy online today.
Next action: If you want a non-injectable option, the real one is an oral tablet — see the format comparison — and it requires a prescription. Discuss it with a licensed prescriber.
Primary sources: Bos JD, Meinardi MM — Experimental Dermatology, 2000 (PMID 10839713), U.S. Food & Drug Administration, DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration
General education, not medical advice. This page is not a review of any specific product.
Why the size problem is decisive
Transdermal patches are a genuine, well-established delivery route — for the right molecules. Nicotine works in a patch because nicotine is small: about 162 Daltons. The outermost layer of skin, the stratum corneum, is an effective barrier, and the practical threshold for getting through it passively has been put at roughly 500 Daltons since Bos and Meinardi’s 2000 review.
| Molecule | Molecular weight | Crosses intact skin passively? |
|---|---|---|
| Nicotine | ~162 Da | Yes — well under the limit, and patches are approved |
| Practical thresholdBos & Meinardi, 2000 | ~500 Da | The upper bound |
| Semaglutide | ~4,113.58 Da | No — about 8× over the limit |
This is the rare case where you do not have to weigh competing studies. A molecule that size does not cross intact skin on its own, and no amount of marketing changes the number.
So what is actually in the patches being sold?
We have not laboratory-tested any product, and we are not naming or reviewing specific brands. But the category divides fairly cleanly:
Herbal or botanical patches
Marketed for “metabolism” or “belly fat,” containing plant extracts. Whatever their merits, they are not delivering a GLP-1 receptor agonist, and the same size barrier applies to most of their ingredients too.
Acupressure or acupoint stickers
These do not claim to deliver a drug at all. They are placed on the body rather than absorbed, and their marketing usually borrows the GLP-1 name without asserting the molecule is present.
“Peptide” topical products
The most misleading group, because the word peptide implies the real thing. A peptide in a cream or patch faces exactly the barrier described above. Presence in the product is not the same as delivery into the bloodstream.
The version of this that is genuinely dangerous
Some sellers offer unapproved semaglutide as a liquid or powder labelled “for research purposes only” or “not for human consumption,” while supplying dosing instructions. The FDA has issued warning letters over exactly this. These products are not reviewed for identity, purity, sterility, or strength, and the agency has also documented fraudulent compounded products whose labels name pharmacies that do not exist.
A “research use only” label is not a technicality to work around. It is the seller stating the product was never intended to go into a person.
What to do if you want to avoid injections
This is a completely reasonable thing to want, and there is a real answer to it. Three oral GLP-1 medications are now FDA-approved: Rybelsus and Wegovy tablets (both oral semaglutide) and Foundayo (orforglipron), approved in April 2026. All three require a prescription. See how the formats compare, or how these medications work for the underlying mechanism.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- The 500 Dalton rule for the skin penetration of chemical compounds and drugsBos JD, Meinardi MM — Experimental Dermatology, 2000 (PMID 10839713)Supports: The ~500 Dalton upper limit for passive penetration of intact skin, which semaglutide exceeds several times over.
- FDA intends to take action against non-FDA-approved GLP-1 drugsU.S. Food & Drug AdministrationSupports: FDA's position on unapproved GLP-1 products sold direct to consumers, including those labelled for research use.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved dosage forms for every semaglutide and tirzepatide product — all injection or oral tablet.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and dosage form, checkable in Drugs@FDA and the Orange Book.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.